PAA Shareholder Questions - Comments for 2019 AGM., page-2

Hi MM,

nice to see you around here

I've got a few

1. most obviously, what in the world is going on with the phase 2 trials - current status,
1a. are we trying to recruit all dogs AND THEN start dosing OR first in first served as the canines come
1b. confirmation of duration of trials? how do they plan to report to the market eg-each dog after 2 weeks or group of dogs after days (this question is probably an extension of 1a. above)

2. Co has mentioned few times, "fast track human trials" - what exactly do they mean by this and can they go into a little more detail, esp when I would have thought they can't do much until ALL the relevant data is collated and interpreted (may take many months?)

3. What was the thinking behind this CR esp. when they previously said they were fully funded for phase 2 trials AND to initiate human trials

4. Can they elaborate and confirm the Elanco option and whether they will go down the upfront fee + royalty option as hinted at previously (bit of confirmation here)

TIA MM